Safety and efficacy of SOM3355 in patients with Huntington’s disease (SOMCT03): a phase 2b, randomised, placebo-controlled, multicentre, dose-ranging study
Summary Background SOM3355 is a β1-blocker and a vesicular monoamine transporter type 1 and 2 inhibitor developed for the treatment of Huntington's disease (HD). Its novel polypharmacology makes it suited for the effective and safe treatment of chorea and other HD symptoms. Methods SOMCT03 was a double-blind, randomise...